CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression

Clinical Infectious Diseases

Volumn 44, Issue 3, 2007, Pages 441-446

  Moore, Richard D ^a,b   Keruly, Jeanne C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; DRUG ABUSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SUSTAINED VIROLOGIC SUPPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIERS ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 33846439783     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510746     Document Type: Article

References (19)

1. Viand JP, Burgard M, Hubert JB, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-DNA level. AIDS 2004; 18:45-9.
2. Hunt PW, Deeks SG, Rodriquez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17:1907-15.
3. Smith CJ, Sabin CA, Youle MS, et al. Factors influencing increases in CD4 cell counts of HIV positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004; 190:1860-8.
4. Michael CG, Kirk O, Mathiesen L, Nielsen SD. The naïve CD4 count in HIV-1-infected patients at time of initiation of highly active anti-retroviral therapy is strongly associated with the level of immunological recovery. Scand J Infect Dis 2002; 34:45-9.
5. Garcia F, de Lazzari E, Plana M, et al. Long-term CD4 T-cell response to highly active antiretroviral therapy according to baseline CD4 T-cell count. J Acquir Immune Defic Syndr 2004; 36:702-13.
6. Florence E, Lundgren J, Dreezen C, et al. for the EuroSIDA Study Group. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Medicine 2003; 4:255-62.
7. Gras L, Van Sighem A, Fraser C, et al. and ATHENA Cohort Study Group. Predictors for changes in CD4 cell count 7 years after starting HAART [abstract 530]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver, CO). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
8. Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3.5 years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:168-75.
9. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17(Suppl 1):S38-41.
10. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents-May 4, 2006. Available at: http://www.aidsinfo .nih.gov/Guidelines/GuidelineDetail.aspx. Accessed 23 September 2006.
11. Braitstein P, Zala C, Yip B, et al. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis 2006; 193:259-68.
12. Law WP, Duncombe CJ, Mahanontharit AP, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004; 18:1169-77.
13. Lucas G, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16:767-74.
14. Dronda F, Zamora J, Moreno S, et al. CD4 cell recovery during successful antiretroviral therapy in naïve HIV-infected patients: the role of intravenous drug use. AIDS 2004; 18:2210-2.
15. Pulido F, Arribas JR, Miro JM, et al. Clinical, virologic, and immunologic response to efavirenz- or pro tease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patient with advanced HIV infection (EfaVIP 2 Study). J Acquir Immune Defic Syndr 2004; 35:343-50.
16. Waters L, Stebbing J, Jones R, et al. A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts. J Antimicrob Chemother 2004; 54:503-7.
17. Riddler SA, Haubrich R, DiRienzo G, et al. A prospective, randomized, phase III trial of NRTI-, PI- and NNRTI-sparing regimens for initial treatment of HIV-1 infection-ACTG 5142 [abstract THLB0204], AIDS Clinical Trials Group 5142 Study Team. In: Program and abstracts of the 16th International AIDS Conference (Toronto, Ontario). Stockholm: International AIDS Society, 2006.
18. Evans TG, Bonnez W, Soucier HR, et al. Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells. Anviral Res 1998; 39:163-73.
19. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208-14.